Metis TechBio Co., Ltd. 劑泰科技 (北 京 ) 股份有限公司 (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liability) WARNING The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is ...

Core Viewpoint - The article discusses the upcoming IPO of Jitai Technology, a biotech company focused on AI-driven nanomaterials, which is expected to soon disclose its PHIP documents and complete its listing on the Hong Kong Stock Exchange [3]. Company Overview - Jitai Technology was founded in 2020 by Dr. Chen Hongmin, a member of the U.S. National Academy of Engineering, along with MIT scientists Dr. Lai Caida and Dr. Wang Wenshou [3]. - The company specializes in targeted drug delivery and discovery technologies to help combat diseases and aging, aiming to restore health and vitality [3]. Technological Innovations - Jitai Technology has developed the world's first AI-driven nanodelivery platform, NanoForge, and possesses the largest global library of LNP (lipid nanoparticles) with over 10 million variants [4]. - The company has created three core solutions based on NanoForge: AiLNP (AI nanodelivery system design platform), AiRNA (AI mRNA sequence design platform), and AiTEM (AI small molecule formulation design platform) [4]. - Jitai Technology has achieved breakthroughs in targeted delivery to eight key organs or tissues, addressing challenges in multi-organ and multi-tissue targeting, providing drug opportunities for various diseases including tumors and neurodegenerative disorders [4]. Clinical Developments - The pipeline product MTS-004 is China's first AI-enabled new drug that has completed Phase III clinical trials, potentially filling a gap in the PBA treatment field and improving the quality of life for patients with conditions like ALS and swallowing difficulties [4]. - The company is also developing a new generation of immunotherapy strategies through its innovative "rocket + satellite" delivery paradigm, with the pipeline product MTS-105 recognized as an orphan drug by the FDA, aiming to be the first mRNA-encoded TCE therapy for solid tumors globally [4]. Investment and Market Position - Since its establishment, Jitai Technology has secured over 2.5 billion RMB in investments from notable institutions including Jingtaitech, Fengrui Capital, Sequoia China, and others [4]. - The article notes that besides Jitai Technology, several other AI pharmaceutical companies are seeking or have confidentially submitted listing applications to the Hong Kong Stock Exchange [5].

Core Insights - JieTai Technology announced that its AI-driven small molecule formulation optimization platform AiTEM has successfully reached the primary endpoint of Phase III clinical trials for the candidate drug MTS-004, making it the first AI-enabled formulation new drug to complete Phase III trials in China [1][2] - MTS-004 is the first and currently the only drug in China to complete Phase III clinical trials for PBA (Pseudobulbar Affect), addressing a significant gap in the domestic treatment landscape for this condition [1][3] Summary by Sections Drug Development and Clinical Trials - MTS-004 is an innovative oral treatment candidate for PBA, designed as an orally disintegrating tablet (ODT) that dissolves quickly in the mouth without water, improving patient experience and adherence [1][3] - The AiTEM platform, powered by JieTai's proprietary AI nano-delivery platform NanoForge, significantly reduced the preclinical formulation optimization cycle from the industry average of 1-2 years to just 3 months [2] - The Phase III clinical trial involved 264 participants over 9.5 months, led by Professor Fan Dongsheng from Peking University Third Hospital, and included multiple centers across China [2] Clinical Efficacy and Safety - MTS-004 demonstrated good overall safety and clear efficacy in treating PBA secondary to neurological diseases, with statistically significant reductions in average attack frequency after 12 weeks of treatment [3] - The drug showed improvements in various assessments, including CNS-LS scores, CGI-C, PGI-C evaluations, and SF-36 mental health index, indicating enhanced emotional control and quality of life for patients [3] Future Prospects - JieTai plans to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) for MTS-004 in 2026, with potential expansion into indications for swallowing disorders post-approval [3] - The CEO of JieTai emphasized the role of AI in accelerating clinical treatment and addressing unmet patient needs, highlighting the successful completion of the drug's development cycle as a foundation for future projects [4]

Core Insights - The company, JieTai Technology, announced that its self-developed AI-driven small molecule formulation optimization platform, AITEM, has successfully reached the primary endpoint of Phase III clinical trials for the candidate drug MTS-004, making it the first AI-enabled formulation new drug to complete Phase III trials in China [1] - MTS-004 is also the first and currently the only drug to complete Phase III clinical trials for Pseudobulbar Affect (PBA) in China, addressing a significant gap in the domestic treatment landscape for PBA [1] Company Overview - AITEM utilizes JieTai Technology's self-developed AI nano-delivery platform, NanoForge, as its technical engine, employing proprietary algorithms for drug formulation design and optimization [2] - The platform leverages quantum chemistry and molecular dynamics simulations to predict interactions between drugs and excipients, generating nano-level formulation optimization solutions to enhance drug solubility and bioavailability [2] Development Efficiency - In the MTS-004 project, AITEM significantly reduced the preclinical formulation optimization cycle from the industry average of 1-2 years to within 3 months [2] - The timeline from project initiation to the completion of Phase III clinical trials for MTS-004 was only 38 months, representing a substantial improvement in drug development efficiency compared to industry standards [2]

Core Insights - The company, Jitai Technology, has launched the world's first AI-driven nano delivery platform, NanoForge, which integrates quantum chemistry and molecular dynamics simulations for drug delivery optimization [1][2] - NanoForge enables a closed-loop process from molecular generation to formulation design, leveraging a large-scale library of over 10 million LNP lipid structures [1][2] - Jitai Technology has developed three major solutions based on NanoForge: AiLNP, AiRNA, and AiTEM, focusing on nucleic acid delivery, mRNA sequence design, and small molecule formulation design respectively [1][2] Company Developments - Jitai Technology has identified LNP targeted delivery for eight organs or tissues, with over 100 authorized and filed patent applications [2] - The company has successfully developed more than 10 pipeline projects, producing 7 preclinical candidates and advancing 4 clinical projects, with the fastest pipeline reaching the pre-NDA stage [2] - The CEO of Jitai Technology emphasized the shift from biotechnology to tech-driven biology, highlighting the efficiency and technological breakthroughs achieved through the integration of large model innovations and iterative experiments [2] Financial and Strategic Moves - In August, Jitai Technology completed a Series D financing round, raising a total of 400 million yuan, led by the Beijing Pharmaceutical Health Industry Investment Fund and the Daxing District Industrial Investment Fund [2] - The funds raised will accelerate the company's strategic initiatives, including platform automation upgrades, advancement of self-developed product pipelines, deepening international collaborations, and attracting high-end talent [2]